{
    "clinical_study": {
        "@rank": "55542", 
        "brief_summary": {
            "textblock": "To compare the effect of AS-101 to that of placebo on clinical efficacy and immunologic\n      function in HIV positive patients with advanced disease. To compare the effect of AS-101 to\n      that of placebo on occurrence of disease progression in HIV positive patients with advanced\n      disease as defined by: (1) development of new diagnostically confirmed major opportunistic\n      infection(s); or (2) development of AIDS-related dementia. To compare the effect of\n      zidovudine (AZT) plus AS-101 versus AZT alone (placebo arm) on clinical efficacy and\n      immunologic function in patients who require anti-viral therapy due to disease progression.\n      Garlic capsules will be given to all study participants to mask the obvious garlic odor of\n      AS-101."
        }, 
        "brief_title": "A Third-Party Blinded, Placebo Controlled Comparative Study of AS-101 Administered Intravenously in HIV Positive Patients With Advanced Disease", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "HIV Seropositivity"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Standard therapy including acyclovir or ganciclovir for infections that develop\n             during the study period. (Prophylactic acyclovir is not permitted.) Standard therapy\n             for persistent infections may continue.\n\n          -  Immunomodulators or specific therapy for malignancies (including Kaposi's sarcoma)\n             allowed only with permission of Wyeth-Ayerst medical monitor.\n\n          -  Zidovudine (AZT) may be added only if there is disease progression and after the\n             patient has been in the study for a minimum of eight weeks.\n\n          -  Garlic capsules will be given to all study participants to mask side effects of\n             AS-101.\n\n          -  Required:\n\n          -  Accepted standard prophylaxis for patients with prior Pneumocystis carinii pneumonia\n             (PCP).\n\n        Patients must have the following:\n\n          -  Diagnosis of AIDS or AIDS-related complex (ARC).\n\n          -  Life expectancy > 6 months.\n\n          -  Provide written informed consent.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions or symptoms are excluded:\n\n          -  Evidence of severe liver dysfunction (serum albumin < 2.5 g/dl, prothrombin time > 15\n             seconds or SGOT or SGPT > 3 x upper limits of normal), gastrointestinal, renal,\n             respiratory, endocrine, hematologic, cardiovascular system abnormalities or\n             psychiatric disorders which would prevent compliance with the protocol.\n\n          -  Evidence of AIDS related dementia.\n\n          -  Presence of disseminated Kaposi's sarcoma defined as any visceral lesions or > 20\n             cutaneous lesions; or Kaposi's sarcoma without at least one other AIDS defining\n             characteristic.\n\n          -  Presence of any lymphoma.\n\n          -  Active opportunistic infection currently requiring treatment unless the infection has\n             stabilized and continuing treatment is only required to prevent relapse (e.g., CNS\n             toxoplasmosis or resolving tuberculosis).\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Prophylactic acyclovir.\n\n          -  Immunomodulators or specific therapy for malignancies (including Kaposi's sarcoma)\n             allowed only with permission of Wyeth-Ayerst medical monitor.\n\n          -  Zidovudine (AZT) may be added only if there is disease progression and after the\n             patient has been in the study for a minimum of eight weeks.\n\n        Patients with the following are excluded:\n\n          -  Evidence of severe organ dysfunction as defined in Exclusion complications or other\n             specified disease conditions.\n\n          -  Unlikely or unable to comply with the requirements of the protocol.\n\n        Prior Medication:\n\n        Excluded within 8 weeks of study entry:\n\n          -  Any immune stimulation agents such as BCG vaccine, interferons, or other immune\n             modulators within 8 weeks.\n\n          -  Any immunosuppressive agent within 8 weeks.\n\n          -  Excluded within 12 weeks of study entry:\n\n          -  Zidovudine (AZT)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "13 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002033", 
            "org_study_id": "045A", 
            "secondary_id": "753A-202-BR,MX"
        }, 
        "intervention": [
            {
                "intervention_name": "Zidovudine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "AS-101", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Zidovudine", 
                "Ammonium trichloro(dioxoethylene-O,O'-)tellurate"
            ]
        }, 
        "keyword": [
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex", 
            "ammonium trichloro(dioxoethylene-O,O'-)tellurute", 
            "Zidovudine"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Sao Paulo", 
                        "country": "Brazil"
                    }, 
                    "name": "Escola Paulista De-Medicina"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sao Paulo", 
                        "country": "Brazil"
                    }, 
                    "name": "Instituto Do Cancer Arnaldo Vieiro"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sao Paulo", 
                        "country": "Brazil"
                    }, 
                    "name": "Faculdade De-Ciencias Medica Da"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sao Paulo", 
                        "country": "Brazil"
                    }, 
                    "name": "Hosp De-Servidor Publico Estadual"
                }
            }
        ], 
        "location_countries": {
            "country": "Brazil"
        }, 
        "official_title": "A Third-Party Blinded, Placebo Controlled Comparative Study of AS-101 Administered Intravenously in HIV Positive Patients With Advanced Disease", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "reference": {
            "citation": "Amarante JM, Levi GC, Pedro RJ, Galvao PA, Scheinberg M, Levy DS. A double blind controlled study with AS-101 in patients infected with HIV. Int Conf AIDS. 1992 Jul 19-24;8(2):B160 (abstract no PoB 3439)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002033"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Wyeth is now a wholly owned subsidiary of Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 1991"
    }, 
    "geocoordinates": {
        "Escola Paulista De-Medicina": "-23.549 -46.639", 
        "Faculdade De-Ciencias Medica Da": "-23.549 -46.639", 
        "Hosp De-Servidor Publico Estadual": "-23.549 -46.639", 
        "Instituto Do Cancer Arnaldo Vieiro": "-23.549 -46.639"
    }
}